

## Cynata Receives Notice of Allowance For Further Patent in Canada

**Melbourne, Australia; 31 August 2021:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Notice of Allowance has been received from the Canadian Intellectual Property Office (CIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

The Notice of Allowance is sent to the applicant when the CIPO intends to issue a patent. This patent joins a further issued Canadian patent covering the Cymerus technology and builds on the broad IP protection of Cynata’s manufacturing platform and its unique ability to yield highly consistent mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

**Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:**

*“This further patent adds an additional layer to our already comprehensive patent portfolio to protect our unique and proprietary IP. The Cymerus platform enables manufacture of consistent, high-quality mesenchymal stem cells at scale. This unique and valuable characteristic of Cynata’s technology is key to the development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.*

Cynata anticipates that the patent will be granted around early January 2022, with an expiration date of 12 March 2034.

The inventors named on the patent are Professor Igor Slukvin, founder, advisor and shareholder of Cynata and Dr Gene Uenishi.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)

Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in patients with respiratory failure are currently ongoing. Planning is also



underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), diabetic foot ulcers, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**

For personal use only